Wall Street maintains cautious hold on Alexandria Real Estate as life sciences sector faces headwinds
Shares of the life sciences REIT have fallen 29.5% over the past year, lagging the S&P 500 and broader real estate indices as occupancy drops and funding slows.
Wall Street analysts are maintaining a cautious stance on Alexandria Real Estate Equities, with a consensus "Hold" rating across 17 coverage points. The stock has significantly underperformed the broader market, falling 29.5% over the past year and 1.2% year-to-date in 2026. This decline has seen the shares lag behind both the S&P 500 Index and the State Street Real Estate Select Sector SPDR ETF (XLRE), which have posted gains of 9.2% and 10.4% respectively over the same period.
The weakness follows mixed first-quarter 2026 results released on 27 April, which triggered a sharp selloff that saw the stock drop nearly 11.3% in the subsequent trading session. While revenue of $671 million slightly exceeded Wall Street estimates of $668 million, profitability metrics weakened considerably. Adjusted funds from operations (FFO) fell 25% year-on-year to $1.73 per share, and operating occupancy declined to 87.7% from 90.9% in the previous quarter, driven by major lease expirations early in the year.
Investor sentiment has been further dampened by a significant dividend cut and slowing tenant demand within the life sciences sector. Cantor Fitzgerald recently adjusted its outlook, cutting its price target for the stock from $60 to $43 while maintaining a "Neutral" rating. This move reflects growing concerns regarding the company’s operating environment, with analysts forecasting FFO for fiscal 2026 to decline nearly 29% year-on-year to $6.40 per share.
Analyst sentiment has softened slightly over the past month, with the number of "Strong Buy" ratings decreasing from three to two. The current breakdown of the 17 analysts covering the stock includes two "Strong Buy" ratings, 14 "Holds," and one "Strong Sell." Despite the near-term caution, the broader consensus average price target stands at $51.93, implying roughly 7.4% upside from current levels, while the highest target of $70 suggests potential for a larger recovery.
Alexandria Real Estate Equities, a specialized real estate investment trust focused on life sciences, is currently valued at approximately $8.43 billion by market capitalisation. The company, which operates research-driven innovation hubs in key biotechnology markets including Boston, San Francisco, and New York, continues to navigate an uneven operating environment as it adapts to changing funding activity and tenant requirements.
